Loading...

Novo Nordisk A/S Peer Comparison

Metric Value Ranking
Market Cap $592.9 Billion 1/21 NVO
$592.9B
VRTX
$113.7B
REGN
$104.9B
MRNA
$50.8B
SGEN
$43.2B
BNTX
$22.1B
ALNY
$19.1B
BMRN
$14.6B
SRPT
$12.5B
RETA
$6.6B
CRSP
$4.7B
MDGL
$4.6B
TGTX
$2.7B
NTLA
$2.5B
NVAX
$2.0B
DNA
$1.9B
ICPT
$794.7M
CVAC
$779.1M
TERN
$397.1M
HEPA
$6.8M
CWBR
$2.6M
Gross Margin 85% 7/21 ICPT
100%
NTLA
100%
RETA
96%
CRSP
90%
SRPT
89%
BNTX
88%
NVO
85%
VRTX
85%
REGN
83%
TGTX
82%
DNA
81%
ALNY
80%
BMRN
79%
SGEN
75%
MRNA
67%
NVAX
49%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
CVAC
-100%
Profit Margin 39% 4/21 RETA
100%
NTLA
100%
CRSP
45%
NVO
39%
VRTX
38%
BNTX
31%
REGN
23%
SRPT
12%
MRNA
8%
BMRN
3%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
ICPT
-3%
ALNY
-31%
TGTX
-33%
SGEN
-33%
NVAX
-61%
CVAC
-100%
DNA
-100%
EBITDA margin 54% 2/21 NTLA
7169%
NVO
54%
VRTX
40%
CRSP
37%
BNTX
34%
REGN
28%
BMRN
2%
MRNA
0%
ICPT
-3%
SRPT
-7%
ALNY
-23%
TGTX
-28%
SGEN
-34%
NVAX
-59%
MDGL
-100%
CWBR
-100%
HEPA
-100%
TERN
-100%
RETA
-356%
CVAC
-370%
DNA
-512%
Quarterly Revenue $9.6 Billion 2/21 BMRN
$646.2B
NVO
$9.6B
REGN
$3.1B
MRNA
$2.8B
VRTX
$2.5B
BNTX
$1.6B
SGEN
$648.7M
ALNY
$439.7M
SRPT
$396.8M
NVAX
$291.3M
CRSP
$200.0M
ICPT
$88.8M
TGTX
$44.0M
DNA
$34.8M
CVAC
$24.2M
RETA
$22.7M
MDGL
$0
CWBR
$0
HEPA
$0
TERN
$0
NTLA
$1.9M
Quarterly Earnings $3.7 Billion 2/21 BMRN
$20.4B
NVO
$3.7B
VRTX
$968.8M
REGN
$722.0M
BNTX
$503.2M
MRNA
$217.0M
RETA
$193.0M
CRSP
$89.3M
SRPT
$45.7M
ICPT
-$2.8M
CWBR
-$4.3M
HEPA
-$11.1M
TGTX
-$14.4M
TERN
-$21.0M
CVAC
-$92.8M
MDGL
-$112.2M
NTLA
-$132.2M
ALNY
-$137.9M
NVAX
-$178.4M
DNA
-$211.7M
SGEN
-$215.8M
Quarterly Free Cash Flow $782.4 Billion 2/21 REGN
$1.4B
NVO
$782.4M
BNTX
$726.0M
VRTX
$118.5M
BMRN
$20.4M
ICPT
$3.9M
TGTX
-$0
CWBR
-$1.8M
HEPA
-$9.0M
TERN
-$19.4M
ALNY
-$45.1M
CVAC
-$58.8M
DNA
-$61.3M
SRPT
-$62.5M
RETA
-$70.2M
SGEN
-$79.8M
MDGL
-$81.0M
NTLA
-$94.6M
CRSP
-$96.8M
NVAX
-$185.9M
MRNA
-$0
Trailing 4 Quarters Revenue $36.0 Billion 2/21 BMRN
$1.2T
NVO
$36.0B
REGN
$13.1B
VRTX
$9.9B
MRNA
$6.8B
BNTX
$4.2B
SGEN
$2.3B
ALNY
$1.8B
SRPT
$1.2B
NVAX
$818.8M
CRSP
$370.0M
ICPT
$317.7M
DNA
$251.5M
TGTX
$233.7M
CVAC
$58.4M
NTLA
$36.3M
RETA
$24.4M
MDGL
$0
CWBR
$0
HEPA
$0
TERN
$0
Trailing 4 Quarters Earnings $13.2 Billion 2/21 BMRN
$646.2B
NVO
$9.6B
REGN
$3.1B
MRNA
$2.8B
VRTX
$2.5B
BNTX
$1.6B
SGEN
$648.7M
ALNY
$439.7M
SRPT
$396.8M
NVAX
$291.3M
CRSP
$200.0M
ICPT
$88.8M
TGTX
$44.0M
DNA
$34.8M
CVAC
$24.2M
RETA
$22.7M
MDGL
-$0
CWBR
-$0
HEPA
-$0
TERN
-$0
NTLA
-$1.9M
Quarterly Earnings Growth 28% 8/21 BMRN
8182831%
RETA
362%
CRSP
181%
SRPT
142%
TGTX
73%
ALNY
34%
CVAC
34%
NVO
28%
VRTX
18%
NVAX
2%
REGN
-12%
SGEN
-13%
NTLA
-13%
DNA
-22%
MDGL
-28%
TERN
-33%
CWBR
-59%
HEPA
-62%
BNTX
-80%
MRNA
-85%
ICPT
-101%
Annual Earnings Growth 47% 7/21 BMRN
378750%
TGTX
108%
CRSP
76%
RETA
72%
ALNY
69%
DNA
59%
NVO
47%
SRPT
39%
NVAX
21%
CVAC
5%
CWBR
1%
VRTX
0%
NTLA
-3%
REGN
-13%
MDGL
-13%
SGEN
-26%
TERN
-36%
HEPA
-50%
BNTX
-88%
ICPT
-124%
MRNA
-203%
Quarterly Revenue Growth 22% 9/21 CRSP
3333233%
BMRN
120116%
TGTX
54864%
RETA
2885%
CVAC
88%
SRPT
54%
ALNY
31%
SGEN
27%
NVO
22%
ICPT
14%
VRTX
9%
NVAX
1%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
REGN
-1%
MRNA
-45%
BNTX
-65%
DNA
-65%
NTLA
-114%
Annual Revenue Growth 24% 8/21 CRSP
128372%
TGTX
64448%
BMRN
60412%
RETA
596%
NTLA
167%
ALNY
62%
SRPT
31%
NVO
24%
CVAC
17%
SGEN
15%
ICPT
8%
VRTX
6%
MDGL
0%
CWBR
0%
HEPA
0%
TERN
0%
REGN
-2%
DNA
-15%
MRNA
-55%
NVAX
-67%
BNTX
-74%
Cash On Hand $932.7 Million 7/21 BMRN
$755.1B
BNTX
$12.8B
VRTX
$10.4B
MRNA
$2.9B
REGN
$2.6B
DNA
$944.1M
NVO
$932.7M
ALNY
$812.7M
NVAX
$578.9M
CVAC
$442.6M
SGEN
$428.6M
SRPT
$428.4M
CRSP
$389.5M
NTLA
$226.7M
TGTX
$217.5M
ICPT
$102.7M
MDGL
$99.9M
TERN
$79.9M
RETA
$48.8M
HEPA
$14.8M
CWBR
$6.2M
Short Term Debt $1.5 Billion 2/21 BMRN
$493.9B
NVO
$1.5B
SRPT
$123.3M
ALNY
$96.5M
VRTX
$83.7M
MRNA
$63.0M
BNTX
$30.9M
NVAX
$28.1M
NTLA
$18.6M
CRSP
$15.6M
CVAC
$5.5M
RETA
$2.5M
TERN
$603,000
MDGL
$527,000
HEPA
$115,916
REGN
$1
TGTX
-$0
SGEN
-$0
ICPT
-$0
CWBR
-$0
DNA
-$0
Long Term Debt $2.5 Billion 2/21 BMRN
$593.1B
NVO
$2.5B
ALNY
$2.3B
REGN
$2.0B
SRPT
$1.3B
MRNA
$1.2B
VRTX
$724.7M
ICPT
$223.9M
CRSP
$223.0M
DNA
$221.8M
BNTX
$209.9M
NVAX
$168.0M
RETA
$163.5M
MDGL
$115.5M
SGEN
$113.5M
NTLA
$96.7M
HEPA
$93,104
TGTX
$0
CWBR
$0
CVAC
$0
TERN
$0
PE 45.03 2/21 TGTX
202.78
NVO
45.03
VRTX
31.41
REGN
27.19
BNTX
21.62
BMRN
0.19
NVAX
-1.00
ALNY
-1.00
RETA
-1.00
SRPT
-1.00
SGEN
-1.00
ICPT
-1.00
MDGL
-1.00
NTLA
-1.00
CRSP
-1.00
CWBR
-1.00
HEPA
-1.00
MRNA
-1.00
CVAC
-1.00
TERN
-1.00
DNA
-1.00
PS 111.59 2/21 RETA
269.17
NVO
111.59
NTLA
69.60
SGEN
18.76
CRSP
12.78
CVAC
12.13
VRTX
11.52
TGTX
11.52
ALNY
10.46
SRPT
10.09
REGN
8.01
MRNA
7.43
DNA
7.39
BNTX
4.79
ICPT
2.50
NVAX
2.47
BMRN
0.01
MDGL
-1.00
CWBR
-1.00
HEPA
-1.00
TERN
-1.00
PB 40.64 2/21 RETA
75.22
NVO
40.64
SGEN
16.92
SRPT
14.60
MDGL
11.42
ICPT
11.06
TGTX
8.17
VRTX
6.47
REGN
3.89
MRNA
3.67
CRSP
2.51
NTLA
2.40
DNA
1.69
TERN
1.56
CVAC
1.37
BNTX
0.99
HEPA
0.93
CWBR
0.27
NVAX
0.00
ALNY
0.00
BMRN
0.00
PC 635.64 1/21 NVO
635.64
RETA
134.44
SGEN
100.70
MDGL
46.32
REGN
40.31
SRPT
29.29
ALNY
23.54
MRNA
17.49
TGTX
12.38
CRSP
12.14
NTLA
11.13
VRTX
10.96
ICPT
7.74
TERN
4.97
NVAX
3.49
DNA
1.97
CVAC
1.76
BNTX
1.72
HEPA
0.46
CWBR
0.41
BMRN
0.02
Liabilities to Equity 2.02 4/21 RETA
4.76
ICPT
4.47
SRPT
2.80
NVO
2.02
HEPA
1.49
MDGL
0.58
CVAC
0.52
DNA
0.52
SGEN
0.42
BMRN
0.38
MRNA
0.33
CWBR
0.32
VRTX
0.29
REGN
0.27
NTLA
0.24
CRSP
0.18
BNTX
0.14
TERN
0.05
NVAX
0.00
ALNY
0.00
TGTX
0.00
ROA 0.04 3/21 VRTX
16%
REGN
11%
NVO
4%
TGTX
4%
BNTX
4%
BMRN
1%
CRSP
-7%
ALNY
-11%
ICPT
-15%
RETA
-16%
SRPT
-16%
SGEN
-21%
MRNA
-26%
NVAX
-29%
TERN
-34%
NTLA
-36%
CVAC
-36%
DNA
-54%
MDGL
-58%
CWBR
-99%
HEPA
-271%
ROE 0.13 5/21 ALNY
200%
NVAX
76%
VRTX
21%
REGN
14%
NVO
13%
TGTX
8%
BNTX
5%
BMRN
2%
CRSP
-8%
SGEN
-29%
MRNA
-34%
TERN
-35%
NTLA
-45%
CVAC
-55%
SRPT
-62%
DNA
-81%
ICPT
-82%
MDGL
-92%
RETA
-94%
CWBR
-131%
HEPA
-673%
Current Ratio 1.49 15/21 TERN
20.42
BNTX
8.33
CRSP
6.43
NTLA
5.19
REGN
4.66
VRTX
4.41
CWBR
4.17
MRNA
4.03
BMRN
3.62
SGEN
3.35
DNA
2.93
CVAC
2.91
MDGL
2.72
HEPA
1.67
NVO
1.49
SRPT
1.36
ICPT
1.22
RETA
1.21
ALNY
0.95
NVAX
0.72
TGTX
-1.00
Quick Ratio 0.05 20/21 TGTX
202.78
NVO
45.03
VRTX
31.41
REGN
27.19
BNTX
21.62
BMRN
0.19
NVAX
-1.00
ALNY
-1.00
RETA
-1.00
SRPT
-1.00
SGEN
-1.00
ICPT
-1.00
MDGL
-1.00
NTLA
-1.00
CRSP
-1.00
CWBR
-1.00
HEPA
-1.00
MRNA
-1.00
CVAC
-1.00
TERN
-1.00
DNA
-1.00
Long Term Debt to Equity 0.17 6/21 ICPT}
3.12
RETA}
1.87
SRPT}
1.48
MDGL}
0.28
DNA}
0.20
NVO}
0.17
BMRN}
0.12
CRSP}
0.12
NTLA}
0.09
MRNA}
0.09
REGN}
0.07
VRTX}
0.04
SGEN}
0.04
HEPA}
0.01
BNTX}
0.01
TGTX}
0.00
CWBR}
0.00
CVAC}
0.00
TERN}
0.00
NVAX}
-0.23
ALNY}
-10.62
Debt to Equity 0.27 5/21 ICPT
3.12
RETA
1.90
SRPT
1.63
MDGL
0.29
NVO
0.27
BMRN
0.22
DNA
0.20
CRSP
0.13
NTLA
0.11
REGN
0.10
MRNA
0.09
CVAC
0.08
VRTX
0.05
SGEN
0.04
HEPA
0.03
BNTX
0.01
TGTX
0.00
CWBR
0.00
TERN
0.00
NVAX
-0.39
ALNY
-12.16
Burn Rate -11.80 19/21 TGTX
15.09
SRPT
11.86
ICPT
8.75
BMRN
5.95
CVAC
4.28
DNA
4.28
TERN
3.78
ALNY
3.18
NVAX
3.01
SGEN
1.95
NTLA
1.61
CWBR
1.43
HEPA
1.33
MDGL
0.85
RETA
-0.26
REGN
-4.05
CRSP
-5.09
VRTX
-11.29
NVO
-11.80
MRNA
-19.06
BNTX
-23.88
Cash to Cap 0.00 21/21 BMRN
51.67
CWBR
2.42
HEPA
2.18
BNTX
0.58
CVAC
0.57
DNA
0.51
NVAX
0.29
TERN
0.20
ICPT
0.13
VRTX
0.09
NTLA
0.09
TGTX
0.08
CRSP
0.08
MRNA
0.06
ALNY
0.04
SRPT
0.03
REGN
0.02
MDGL
0.02
RETA
0.01
SGEN
0.01
NVO
0.00
CCR 0.21 13/21 REGN
1.87
BNTX
1.44
NVAX
1.04
TERN
0.92
HEPA
0.81
MDGL
0.72
NTLA
0.72
CVAC
0.63
CWBR
0.42
SGEN
0.37
ALNY
0.33
DNA
0.29
NVO
0.21
VRTX
0.12
BMRN
0.00
TGTX
0.00
RETA
-0.36
CRSP
-1.08
SRPT
-1.37
ICPT
-1.38
MRNA
EV to EBITDA 3.06 7/21 MRNA}
8193.21
REGN}
120.33
VRTX}
102.32
CRSP}
61.44
BNTX}
25.32
BMRN}
24.37
NVO}
3.06
MDGL}
-1.00
CWBR}
-1.00
HEPA}
-1.00
TERN}
-1.00
CVAC}
-6.09
DNA}
-6.37
NVAX}
-9.98
NTLA}
-17.56
RETA}
-82.50
SGEN}
-191.83
TGTX}
-198.21
ALNY}
-204.02
ICPT}
-331.82
SRPT}
-474.89
EV to Revenue 3.00 14/21 RETA
273.97
NTLA
66.53
SGEN
18.62
CRSP
12.37
ALNY
11.49
SRPT
10.87
TGTX
10.59
VRTX
10.55
CVAC
8.47
REGN
8.02
MRNA
7.18
DNA
4.51
BNTX
3.06
NVO
3.00
ICPT
2.88
NVAX
2.10
BMRN
0.28
MDGL
-1.00
CWBR
-1.00
HEPA
-1.00
TERN
-1.00